Document is current
Any future updates will be listed below
-
Authors
Koslowski, Michael https://orcid.org/0000-0001-8798-9875
Johnson, Matthew W.
Gründer, Gerhard
Betzler, Felix
-
Funding
Funding for this research was provided by:
Charité - Universitätsmedizin Berlin
- License Information
-
More Information
Article History
Accepted: 29 September 2021
First Online: 13 November 2021
Change Date: 15 August 2022
Change Type: Update
Change Details: Missing Open Access funding information has been added in the Funding Note.
Declarations
:
: This article does not contain any studies with human or animal subjects performed by any of the authors.
: MK and FB declare no competing interests. GG has served as a consultant for Allergan (Dublin, Ireland), Boehringer Ingelheim (Ingelheim, Germany), Institute for Quality and Efficiency in Health Care (IQWiG, Cologne, Germany), Janssen-Cilag (Neuss, Germany), Lundbeck (Copenhagen, Denmark), Otsuka (Chiyoda, Japan), Recordati (Milan, Italy), Sage (Cambridge, USA), and Takeda (Osaka, Japan). He has served on the speakers’ bureau of Gedeon Richter (Budapest, Hungary), Janssen Cilag, Lundbeck, Otsuka, Recordati. He has received grant support from Boehringer Ingelheim, Lundbeck and Saladax (Bethlehem, USA). He is co-founder and/or shareholder of Mind and Brain Institute GmbH (Zornheim, Germany), Brainfoods GmbH (Zornheim, Germany), OVID Health Systems GmbH (Berlin, Germany) and MIND Foundation gGmbH (Berlin, Germany). MWJ is in advisory relationships with the following organizations regarding the medical development of psychedelics and related compounds: AWAKN Life Sciences, Beckley Psytech, Entheon Biomedical, Field Trip Psychedelics, Mind Medicine, Otsuka Pharmaceutical Development & Commercialization, and Silo Pharma.
